 Catherine Derington
Concepts (127)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Antihypertensive Agents | 27 | 2025 | 494 | 6.050 |
Why?
| | Hypertension | 27 | 2025 | 1295 | 5.360 |
Why?
| | Angiotensin Receptor Antagonists | 6 | 2025 | 92 | 2.050 |
Why?
| | Angiotensin-Converting Enzyme Inhibitors | 5 | 2025 | 201 | 1.780 |
Why?
| | Blood Pressure | 20 | 2024 | 1786 | 1.730 |
Why?
| | Dementia | 4 | 2025 | 259 | 1.160 |
Why?
| | Veterans | 7 | 2025 | 1476 | 1.040 |
Why?
| | Atherosclerosis | 4 | 2023 | 415 | 0.970 |
Why?
| | Cognitive Dysfunction | 3 | 2025 | 383 | 0.910 |
Why?
| | Adrenergic beta-Antagonists | 3 | 2025 | 323 | 0.910 |
Why?
| | Authorship | 1 | 2025 | 53 | 0.890 |
Why?
| | Publishing | 1 | 2025 | 147 | 0.810 |
Why?
| | Empathy | 1 | 2025 | 173 | 0.780 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 5 | 2024 | 445 | 0.740 |
Why?
| | Losartan | 1 | 2020 | 14 | 0.690 |
Why?
| | Lisinopril | 1 | 2020 | 13 | 0.690 |
Why?
| | Nutrition Surveys | 7 | 2023 | 266 | 0.690 |
Why?
| | Angioedema | 1 | 2020 | 16 | 0.680 |
Why?
| | Aged | 28 | 2025 | 23961 | 0.680 |
Why?
| | Hypercholesterolemia | 1 | 2021 | 106 | 0.650 |
Why?
| | Naloxone | 1 | 2020 | 122 | 0.640 |
Why?
| | Elective Surgical Procedures | 1 | 2020 | 179 | 0.600 |
Why?
| | Atrial Fibrillation | 1 | 2023 | 388 | 0.590 |
Why?
| | Cardiovascular Diseases | 8 | 2025 | 2111 | 0.550 |
Why?
| | Heart Diseases | 1 | 2020 | 346 | 0.520 |
Why?
| | Drug Overdose | 1 | 2020 | 347 | 0.500 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2021 | 804 | 0.470 |
Why?
| | United States | 17 | 2025 | 14841 | 0.470 |
Why?
| | Humans | 46 | 2025 | 137585 | 0.450 |
Why?
| | Percutaneous Coronary Intervention | 1 | 2020 | 480 | 0.450 |
Why?
| | Insulin Glargine | 2 | 2025 | 84 | 0.450 |
Why?
| | Stroke | 1 | 2023 | 1120 | 0.450 |
Why?
| | Male | 27 | 2025 | 67762 | 0.400 |
Why?
| | Medication Adherence | 5 | 2024 | 467 | 0.390 |
Why?
| | Middle Aged | 18 | 2025 | 33479 | 0.380 |
Why?
| | Cross-Sectional Studies | 10 | 2025 | 5472 | 0.380 |
Why?
| | Female | 27 | 2025 | 73304 | 0.380 |
Why?
| | Cost-Benefit Analysis | 4 | 2023 | 591 | 0.370 |
Why?
| | Anticholesteremic Agents | 2 | 2022 | 153 | 0.330 |
Why?
| | Risk Factors | 9 | 2025 | 10388 | 0.320 |
Why?
| | Retrospective Studies | 8 | 2023 | 15657 | 0.290 |
Why?
| | Adult | 15 | 2024 | 37929 | 0.290 |
Why?
| | Drug Combinations | 4 | 2023 | 343 | 0.280 |
Why?
| | Follow-Up Studies | 5 | 2022 | 5131 | 0.250 |
Why?
| | Hypoglycemic Agents | 2 | 2025 | 1291 | 0.250 |
Why?
| | Cholesterol, LDL | 3 | 2024 | 365 | 0.240 |
Why?
| | Eicosapentaenoic Acid | 2 | 2023 | 39 | 0.240 |
Why?
| | Ezetimibe | 2 | 2022 | 24 | 0.230 |
Why?
| | Grief | 1 | 2025 | 38 | 0.230 |
Why?
| | Databases, Factual | 2 | 2020 | 1357 | 0.220 |
Why?
| | Myocardial Infarction | 2 | 2022 | 1046 | 0.220 |
Why?
| | Drug Therapy, Combination | 3 | 2024 | 1066 | 0.220 |
Why?
| | United States Department of Veterans Affairs | 2 | 2025 | 678 | 0.220 |
Why?
| | Proportional Hazards Models | 3 | 2022 | 1266 | 0.210 |
Why?
| | Pharmacies | 1 | 2024 | 38 | 0.210 |
Why?
| | Health Care Costs | 2 | 2024 | 398 | 0.210 |
Why?
| | Pharmacy | 1 | 2024 | 32 | 0.210 |
Why?
| | Aged, 80 and over | 5 | 2024 | 7635 | 0.210 |
Why?
| | Thiazides | 1 | 2022 | 2 | 0.200 |
Why?
| | Gastrointestinal Diseases | 1 | 2025 | 209 | 0.200 |
Why?
| | Warfarin | 1 | 2023 | 154 | 0.190 |
Why?
| | Receptor, Angiotensin, Type 2 | 1 | 2022 | 9 | 0.190 |
Why?
| | Receptor, Angiotensin, Type 1 | 1 | 2022 | 25 | 0.190 |
Why?
| | Calcium Channel Blockers | 1 | 2022 | 167 | 0.180 |
Why?
| | Hyperlipidemias | 1 | 2022 | 120 | 0.180 |
Why?
| | Healthcare Disparities | 2 | 2024 | 654 | 0.170 |
Why?
| | Diabetes Mellitus, Type 2 | 2 | 2025 | 2531 | 0.170 |
Why?
| | Social Determinants of Health | 1 | 2024 | 267 | 0.170 |
Why?
| | Cardiology | 1 | 2023 | 274 | 0.170 |
Why?
| | Hospitalization | 2 | 2021 | 2199 | 0.170 |
Why?
| | Frailty | 1 | 2023 | 170 | 0.160 |
Why?
| | Data Mining | 1 | 2020 | 116 | 0.160 |
Why?
| | Angina, Stable | 1 | 2019 | 17 | 0.160 |
Why?
| | Costs and Cost Analysis | 1 | 2020 | 213 | 0.160 |
Why?
| | Propensity Score | 1 | 2021 | 294 | 0.160 |
Why?
| | Drug-Related Side Effects and Adverse Reactions | 1 | 2021 | 250 | 0.150 |
Why?
| | Drug Administration Schedule | 1 | 2020 | 786 | 0.150 |
Why?
| | Anticoagulants | 1 | 2023 | 664 | 0.150 |
Why?
| | Goals | 1 | 2019 | 170 | 0.140 |
Why?
| | Coronary Angiography | 1 | 2020 | 317 | 0.140 |
Why?
| | Veterans Health | 1 | 2019 | 186 | 0.140 |
Why?
| | Randomized Controlled Trials as Topic | 2 | 2022 | 1477 | 0.130 |
Why?
| | Patient Selection | 1 | 2021 | 696 | 0.130 |
Why?
| | Exercise Test | 1 | 2020 | 625 | 0.130 |
Why?
| | Decision Support Systems, Clinical | 1 | 2020 | 226 | 0.130 |
Why?
| | Survival Rate | 1 | 2021 | 1972 | 0.130 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2020 | 2057 | 0.130 |
Why?
| | Sex Characteristics | 1 | 2021 | 762 | 0.120 |
Why?
| | Electronic Health Records | 2 | 2020 | 1069 | 0.120 |
Why?
| | Practice Patterns, Physicians' | 1 | 2024 | 1313 | 0.120 |
Why?
| | Cohort Studies | 2 | 2023 | 5742 | 0.120 |
Why?
| | Coronary Artery Disease | 1 | 2021 | 698 | 0.110 |
Why?
| | Patient Care Team | 1 | 2019 | 631 | 0.110 |
Why?
| | Health Personnel | 1 | 2020 | 710 | 0.110 |
Why?
| | Case-Control Studies | 1 | 2021 | 3556 | 0.100 |
Why?
| | Treatment Outcome | 3 | 2025 | 10811 | 0.100 |
Why?
| | Patient Acceptance of Health Care | 1 | 2019 | 806 | 0.100 |
Why?
| | Algorithms | 1 | 2020 | 1704 | 0.100 |
Why?
| | Primary Prevention | 2 | 2023 | 196 | 0.090 |
Why?
| | Prevalence | 3 | 2023 | 2734 | 0.090 |
Why?
| | Heart Failure | 1 | 2024 | 2236 | 0.090 |
Why?
| | Time Factors | 1 | 2021 | 6828 | 0.080 |
Why?
| | Biomarkers | 1 | 2021 | 4149 | 0.080 |
Why?
| | Primary Health Care | 1 | 2020 | 1738 | 0.080 |
Why?
| | Practice Guidelines as Topic | 2 | 2024 | 1587 | 0.060 |
Why?
| | Medicare Part D | 1 | 2024 | 25 | 0.060 |
Why?
| | Mineralocorticoid Receptor Antagonists | 1 | 2024 | 54 | 0.050 |
Why?
| | Quality-Adjusted Life Years | 1 | 2023 | 113 | 0.050 |
Why?
| | Drug Costs | 1 | 2024 | 106 | 0.050 |
Why?
| | Renin-Angiotensin System | 1 | 2023 | 85 | 0.050 |
Why?
| | Drug Prescriptions | 1 | 2024 | 245 | 0.050 |
Why?
| | Stroke Volume | 1 | 2024 | 612 | 0.040 |
Why?
| | Metformin | 1 | 2025 | 331 | 0.040 |
Why?
| | Adolescent | 1 | 2020 | 21513 | 0.040 |
Why?
| | Evaluation Studies as Topic | 1 | 2020 | 180 | 0.040 |
Why?
| | Self Report | 1 | 2024 | 827 | 0.040 |
Why?
| | Health Status Disparities | 1 | 2022 | 289 | 0.040 |
Why?
| | Medicare | 1 | 2023 | 773 | 0.030 |
Why?
| | Antiviral Agents | 1 | 2023 | 744 | 0.030 |
Why?
| | Registries | 1 | 2024 | 2035 | 0.030 |
Why?
| | Cognition | 1 | 2023 | 1153 | 0.030 |
Why?
| | Incidence | 1 | 2022 | 2804 | 0.030 |
Why?
| | Pandemics | 1 | 2023 | 1639 | 0.030 |
Why?
| | Aging | 1 | 2024 | 1864 | 0.030 |
Why?
| | Risk Assessment | 1 | 2021 | 3457 | 0.020 |
Why?
| | Severity of Illness Index | 1 | 2019 | 2828 | 0.020 |
Why?
| | Young Adult | 1 | 2021 | 13209 | 0.010 |
Why?
|
|
Derington's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|